Pharma Stocks
-
Pharma stock jumps 9% after signing $11.75 Bil deal to acquire US-based firm
Synopsis:- Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon & Co. for $14 per share in an…
Read More » -
Sun Pharma shares jump over 7% after firm announces plan to acquire US-based Organon at $11.75 billion valuation
Upstox Securities Pvt. Ltd.: SEBI Registration No. INZ000315837 | NSE TM Code: 13942 | BSE TM Code: 6155 | CDSL…
Read More » -
Is its pharma packaging moat strong enough to unlock new upsid
As demand for drug delivery systems surges globally, can Gerresheimer’s specialized manufacturing edge deliver reliable returns for you? This report…
Read More » -
Why Google Discover changes matter more now
Google’s 2026 Discover Core Update is reshaping how you access AstraZeneca plc stock (GB0009895292) insights on mobile, pushing personalized pharma…
Read More » -
Why Google’s 2026 Discover update matters more now for pharma in
Google’s 2026 Discover Core Update pushes personalized, mobile-first financial content on Almirall S.A. stock (ES0157097017) directly into your feed, giving…
Read More » -
InnoCare Pharma Limited Just Missed Revenue By 19%: Here’s What Analysts Think Will Happen Next
Last week, you might have seen that InnoCare Pharma Limited (HKG:9969) released its first-quarter result to the market. The early…
Read More » -
A Look At Corcept Therapeutics (CORT) Valuation After Lifyorli’s FDA Approval And Upcoming ROSELLA Phase 3 Data
Corcept Therapeutics (CORT) is back in focus after securing FDA approval for Lifyorli in platinum-resistant ovarian cancer and scheduling Phase…
Read More » -
Regeneron Stock: FDA Approval, Pricing Deal, and a Phase 3 Win in the Same Week
Key Stats for Regeneron Stock 52-Week Range: $476 to $821 Current Price: $752 Street Mean Target: $878 Street High Target:…
Read More » -
Sun Pharma’s Organon Bid: Valuation Doubts Emerge as Stock Falls
Deal Nears Amid Market Skepticism Sun Pharmaceutical Industries is reportedly close to finalizing a $12 billion to $13 billion acquisition…
Read More » -
Vistin Pharma (OB:VISTN) 16.5% Net Margin Tests Slowing Earnings Growth Narrative
Vistin Pharma (OB:VISTN) has come into Q1 2026 with a recent run of solid top and bottom line numbers, capped…
Read More »